corrigendum

Annals of Oncology 25: 300, 2014
doi:10.1093/annonc/mdt534

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

Ann Oncol 2013; 24: 1067–1073 (doi: 10.1093/annonc/mds541

In the 'results' section, subsection 'efficacy', the correct 95% confidence intervals of the complete responses in the overall phase are 57–71% and 40–55% (instead of 16–46% and 10–36%, respectively).

The correct text is below.

efficacy

The percentage of patients who achieved a complete response (no emesis and no rescue therapy) in the overall phase (0–120 h) was significantly higher in the fosaprepitant group than in the control group {64% [95% confidence interval (CI) 57–71%] versus 47% [95% CI 40–55%]; $P = 0.0015$} (Figure 2). Furthermore, in the acute and delayed phases, the percentages of patients with a complete response were significantly higher in the fosaprepitant group than in the control group (acute phase: 94% versus 81%, $P = 0.0006$; delayed phase: 65% versus 49%, $P = 0.0025$). Among the patients who had previously been treated with cisplatin and experienced vomiting, the complete response rates in the overall phase were higher in the fosaprepitant group than in the control group (60.0% versus 30.3%).

The authors apologize for the errors.